Announcements
- Tempest to Participate in Upcoming Investor Conferences
- Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
- Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
- Tempest Reports Year End 2023 Financial Results and Provides Business Update
- Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
- Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
- Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
- Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
More ▼
Key statistics
As of last trade, Tempest Therapeutics Inc (3OS:FRA) traded at 2.94, 1,597.11% above the 52 week low of 0.173 set on Oct 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.94 |
---|---|
High | 2.94 |
Low | 2.94 |
Bid | 2.96 |
Offer | 3.01 |
Previous close | 3.00 |
Average volume | 5.10k |
---|---|
Shares outstanding | 22.22m |
Free float | 22.20m |
P/E (TTM) | -- |
Market cap | 71.32m USD |
EPS (TTM) | -1.76 USD |
Data delayed at least 15 minutes, as of May 24 2024 07:00 BST.
More ▼